Treatment Outcomes of AIDS-Associated Kaposi's Sarcoma under a Routine Antiretroviral Therapy Program in Lilongwe, Malawi: Bleomycin/Vincristine Compared to Vincristine Monotherapy

Purpose Despite Kaposi's sarcoma (KS) being the most prevalent AIDS-associated cancer in resource limited settings, optimal treatment options remain unknown. We assessed whether bleomycin/vincristine compared to vincristine monotherapy was associated with improved treatment outcomes for AIDS-associated KS among patients initiating combination antiretroviral therapy (cART) in Malawi. Methods All patients initiating cART and chemotherapy for AIDS-related KS were identified from an electronic data system from the HIV Lighthouse Clinic from 2002 to 2011. Treatment responses were compared between patients receiving vincristine monotherapy and vincristine/bleomycin. Binomial regression models were implemented to assess probability of tumor improvement for patients receiving vincristine/bleomycin compared to vincristine monotherapy after a complete cycle of chemotherapy (9–10 months). A chi-squared test was used to compare changes in CD4 count after six months of chemotherapy. Results Of 449 patients with AIDS-associated KS on chemotherapy, 94% received vincristine monotherapy and 6% received bleomycin/vincristine. Distribution of treatment outcomes was different: 29% of patients on vincristine experienced tumor improvement compared to 53% of patients on bleomycin/vincristine. Patients receiving bleomycin/vincristine were 2.25 (95% CI: 1.47, 3.44) times as likely to experience tumor improvement as to those on vincristine monotherapy. This value changed little after adjustment for age and baseline CD4 count: 2.46 (95% CI: 1.57, 3.86). Change in CD4 count was similar for patients receiving vincristine monotherapy and bleomycin/vincristine (p = 0.6). Conclusion Bleomycin/vincristine for the treatment of AIDS-associated KS was associated with better tumor response compared to vincristine monotherapy without impairing CD4 count recovery. Replication in larger datasets and randomized controlled trials is necessary.

[1]  D. Scadden,et al.  A Randomized Controlled Trial of Highly Active Antiretroviral Therapy Versus Highly Active Antiretroviral Therapy and Chemotherapy in Therapy-Naive Patients With HIV-Associated Kaposi Sarcoma in South Africa , 2012, Journal of acquired immune deficiency syndromes.

[2]  C. Dzamalala,et al.  Burden of cancer in Malawi; common types, incidence and trends: National population-based cancer registry , 2012, BMC Research Notes.

[3]  L. Kalilani,et al.  A Prospective Study Assessing Tumour Response, Survival, and Palliative Care Outcomes in Patients with HIV-Related Kaposi's Sarcoma at Queen Elizabeth Central Hospital, Blantyre, Malawi , 2012, AIDS research and treatment.

[4]  D. Dittmer,et al.  Treatment of Kaposi Sarcoma-Associated Herpesvirus-Associated Cancers , 2012, Front. Microbio..

[5]  S. Krown.  Treatment strategies for Kaposi sarcoma in sub-Saharan Africa: challenges and opportunities , 2011, Current opinion in oncology.

[6]  D. Whitby,et al.  Update on KSHV epidemiology, Kaposi Sarcoma pathogenesis, and treatment of Kaposi Sarcoma. , 2011, Cancer letters.

[7]  H. Tweya,et al.  Outcomes and associated risk factors of patients traced after being lost to follow-up from antiretroviral treatment in Lilongwe, Malawi , 2011, BMC infectious diseases.

[8]  J. Sterne,et al.  Adjusting Mortality for Loss to Follow-Up: Analysis of Five ART Programmes in Sub-Saharan Africa , 2010, PloS one.

[9]  D. Gareta,et al.  Early active follow‐up of patients on antiretroviral therapy (ART) who are lost to follow‐up: the ‘Back‐to‐Care’ project in Lilongwe, Malawi , 2010, Tropical medicine & international health : TM & IH.

[10]  N. Ford,et al.  Risk factors for mortality in AIDS-associated Kaposi sarcoma in a primary care antiretroviral treatment program in Malawi. , 2010, International health.

[11]  A. Mosam,et al.  Kaposi's sarcoma in sub-Saharan Africa: a current perspective , 2010, Current opinion in infectious diseases.

[12]  N. Ford,et al.  AIDS-associated Kaposi's sarcoma is linked to advanced disease and high mortality in a primary care HIV programme in South Africa , 2010, Journal of the International AIDS Society.

[13]  M. Egger,et al.  Mortality of Patients Lost to Follow-Up in Antiretroviral Treatment Programmes in Resource-Limited Settings: Systematic Review and Meta-Analysis , 2009, PloS one.

[14]  Y. Mlombe.  Management of HIV associated Kaposi's sarcoma in Malawi. , 2009, Malawi medical journal : the journal of Medical Association of Malawi.

[15]  Anthony D Harries,et al.  Outcomes of patients with Kaposi's sarcoma who start antiretroviral therapy under routine programme conditions in Malawi , 2008, Tropical doctor.

[16]  Sydney Rosen,et al.  Patient Retention in Antiretroviral Therapy Programs in Sub-Saharan Africa: A Systematic Review , 2007, PLoS medicine.

[17]  E. Schouten,et al.  True outcomes for patients on antiretroviral therapy who are "lost to follow-up" in Malawi. , 2007, Bulletin of the World Health Organization.

[18]  C. Brander,et al.  Kaposi's sarcoma-associated herpesvirus-specific immune reconstitution and antiviral effect of combined HAART/chemotherapy in HIV clade C-infected individuals with Kaposi's sarcoma , 2007, AIDS.

[19]  C. Polanczyk,et al.  Cost-Effectiveness Analysis Comparing Chemotherapy Regimens in the Treatment of AIDS-Related Kaposi’s Sarcoma in Brazil , 2006, HIV Clinical Trials.

[20]  B. Gazzard,et al.  A prognostic index for AIDS-associated Kaposi's sarcoma in the era of highly active antiretroviral therapy , 2006, The Lancet.

[21]  P. Mayaud,et al.  AIDS‐related Kaposi's sarcoma: epidemiological, diagnostic, treatment and control aspects in sub‐Saharan Africa , 2005, Tropical medicine & international health : TM & IH.

[22]  L. Ivers,et al.  Efficacy of antiretroviral therapy programs in resource-poor settings: a meta-analysis of the published literature. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[23]  S. Krown.  Highly active antiretroviral therapy in AIDS-associated Kaposi's sarcoma: implications for the design of therapeutic trials in patients with advanced, symptomatic Kaposi's sarcoma. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  M. Wildner.  Lost to follow-up. , 1995, The Journal of bone and joint surgery. British volume.

[25]  C. Sabin,et al.  Kaposi's sarcoma in HIV infection treated with vincristine and bleomycin. , 1993, AIDS.

[26]  C. Gilks.  Cancer and HIV infection. , 1991, BMJ.

[27]  J. McCutchan,et al.  Systemic treatment of AIDS-related Kaposi's sarcoma: results of a randomized trial. , 1991, The American journal of medicine.

[28]  M. E. Harb,et al.  Treatment of Advanced Kaposi's Sarcoma Using a Combination of Bleomycin and Vincristine , 1990, American journal of clinical oncology.

[29]  A. Levine,et al.  Advanced acquired immune deficiency syndrome‐related Kaposi's sarcoma. Results of pilot studies using combination chemotherapy , 1990, Cancer.

[30]  S. Krown,et al.  Kaposi's sarcoma in the acquired immune deficiency syndrome: a proposal for uniform evaluation, response, and staging criteria. AIDS Clinical Trials Group Oncology Committee. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  S. Krown,et al.  Kaposi's Sarcoma in the Acquired Immune Deficiency Syndrome: A Proposal for Uniform Evaluation, Response, and Staging Criteria , 1989 .

[32]  F. Real,et al.  Treatment of Kaposi's sarcoma and thrombocytopenia with vincristine in patients with the acquired immunodeficiency syndrome. , 1985, Annals of internal medicine.